According to CoinMeta, DeepMind has launched AlphaGenome 2, which is a AI model designed to predict how changes in DNA affect specific cell types and to assist researchers in investigating disease mechanisms. Alphabet ($GOOGL)'s CEO, Sundar Pichai, emphasized the difference between shared genetic blueprints and the way cells are utilized. This model was trained using over 107 million single-cell datasets and is capable of making predictions for specific tissues, cell types, or biological states. In Tenk10K benchmark tests, AlphaGenome 2 identified 30% of causal variations, an improvement from 16% in earlier models. Its performance in predicting gene activity also increased from 23% to 43%. DeepMind demonstrated how this system links DNA variations to increased ETS2 gene activity associated with inflammatory bowel disease. The model is currently available for non-commercial research purposes, and commercial access is in a private preview phase; it has not yet received diagnostic approval.